| Megan Kathleen Sherrell, PHARMD | |
|
1605 K66 Ste B, Galena, KS 66739-4306 | |
| (620) 783-1636 | |
| Not Available |
| Full Name | Megan Kathleen Sherrell |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 1605 K66 Ste B, Galena, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1669149472 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 1-103635 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Megan Kathleen Sherrell, PHARMD 1605 K66 Ste B, Galena, KS 66739-4306 Ph: (620) 783-1636 | Megan Kathleen Sherrell, PHARMD 1605 K66 Ste B, Galena, KS 66739-4306 Ph: (620) 783-1636 |
News Archive
Female hormones may play a role in women's decreased risk of developing kidney failure relative to men, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The findings may be helpful for future attempts at safeguarding women's and men's kidney health in sex-specific ways.
It's 2020, and as much as we wish it weren't so, sexual harassment is still with us. One need only look at social media or a steady stream of court cases: most recently, the #MeToo movement has cast a light on sexual harassment.
Cardiology experts are supporting a call for greater attention to diagnosis and management of atrial fibrillation in primary care to prevent strokes.
People with diabetes have a three to five times higher risk of contracting tuberculosis (TB) than non-diabetics, according to researchers at The University of Texas Health Science Center at Houston.
Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a serious life-threatening neoplastic condition characterized by varying degrees of bone marrow failure, splenic enlargement and debilitating constitutional symptoms, and INCB28060, an oral cMET inhibitor that is about to enter Phase I development as a potential treatment for multiple cancers.
› Verified 4 days ago
Dr. Mark Steven Mayberry Jr., PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1605 K66, Galena, KS 66739 Phone: 620-783-1636 Fax: 620-783-1690 |